England and Germany ‘neck-and-neck’ in coronavirus vaccine race
Teams at Oxford University and BioNTech are competing to produce the first internationally accepted vaccination for Covid-19
The life-and-death sprint to find a drug that can protect us all from Covid-19 is a contest in which there ought to be no losers.
Yet the unprecedented efforts of the world’s scientists and drug companies to create a coronavirus vaccine have culminated in a familiar rivalry, says The Telegraph - “a playoff between teams in England and Germany”.
The first internationally licensed vaccine is expected to emerge either from Oxford University, in partnership with the Anglo-Swedish pharmaceutical company Astra-Zeneca, or from Germany’s BioNTech and its US-based manufacturing partner Pfizer.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
“Both products have completed successful phase one and two trials, with data suggesting they produced a ‘robust’ immune response - antibodies and T-cells - in volunteers after two doses,” the newspaper reports.
Scores of other potential vaccines are also under development, and in an unconventional move, two have been approved for use in their home countries before undergoing large-scale phase three trials.
Russia is planning to start mass vaccinations in October using a drug created by the Moscow-based Gameleya laboratory, while China will give soldiers a vaccine developed by medical lab CanSino and military researchers.
However, neither the Russian nor Chinese vaccine is likely to gain international acceptance without phase-three clinical trial results to reassure public health officials.
“Russia has released no scientific data as to the safety and effectiveness of its vaccine,” says CNBC.
By contrast, phase three trials of both the BioNTech and Oxford vaccines are well under way, and data from earlier testing has already been published.
“AstraZeneca has indicated they might be able to start delivering emergency vaccines as early as October, depending on the outcome of the studies,” says The New York Times. “Their phase one/two trial revealed that the vaccine was safe, causing no severe side effects.”
Although the German vaccine caused some “moderate side effects such as sleep disturbances and sore arms”, the paper adds, the drug also produced an effective immune response.
Both vaccines are likely to require two doses, according to The Telegraph, and “how long any protective effect will last” remains “unclear”.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Holden Frith is The Week’s digital director. He also makes regular appearances on “The Week Unwrapped”, speaking about subjects as diverse as vaccine development and bionic bomb-sniffing locusts. He joined The Week in 2013, spending five years editing the magazine’s website. Before that, he was deputy digital editor at The Sunday Times. He has also been TheTimes.co.uk’s technology editor and the launch editor of Wired magazine’s UK website. Holden has worked in journalism for nearly two decades, having started his professional career while completing an English literature degree at Cambridge University. He followed that with a master’s degree in journalism from Northwestern University in Chicago. A keen photographer, he also writes travel features whenever he gets the chance.
-
Today's political cartoons - November 3, 2024
Cartoons Sunday's cartoons - presidential pitching, wavering convictions, and more
By The Week US Published
-
Why Man United finally lost patience with ten Hag
Talking Point After another loss United sacked ten Hag in hopes of success in the Champion's League
By The Week UK Published
-
Who are the markets backing in the US election?
Talking Point Speculators are piling in on the Trump trade. A Harris victory would come as a surprise
By The Week UK Published
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
Israel, UN agree to Gaza pauses for polio vaccinations
Speed Read Gaza's first case of polio in 25 years was confirmed last week in a 10-month-old boy who is now partially paralyzed
By Rafi Schwartz, The Week US Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published
-
Mpox: how dangerous is new health emergency?
Today's Big Question Spread of potentially deadly sub-variant more like early days of HIV than Covid, say scientists
By The Week UK Published
-
What is POTS and why is it more common now?
The explainer The condition affecting young women
By Devika Rao, The Week US Published
-
Brexit, Matt Hancock and black swans: five takeaways from Covid inquiry report
The Explainer UK was 'unprepared' for pandemic and government 'failed' citizens with flawed response, says damning report
By Harriet Marsden, The Week UK Published
-
Should masks be here to stay?
Talking Points New York Governor Kathy Hochul proposed a mask ban. Here's why she wants one — and why it may not make sense.
By Anya Jaremko-Greenwold, The Week US Published
-
Covid might be to blame for an uptick in rare cancers
The explainer The virus may be making us more susceptible to certain cancers
By Devika Rao, The Week US Published